Theophylline in the ambulatory treatment of chronic obstructive lung disease: resolving a controversy
Donald G. Vidt, MD
Alan Bakst, PharmD
Gordon L. Snider, MDAddress reprint requests to G.L.S., Chief, Medical Service, Boston VA Medical Center, 150 South Huntington Avenue, Boston, MA 01230.
Recent reports of a high frequency of theophylline toxicity, which usually occurs at theophylline blood levels >20 μ/mL, coupled with the recent addition of metered-dose, inhaled anticholinergics to the beta-2 agonist inhalers already available for treatment of chronic obstructive pulmonary disease, has led some authors to suggest that theophylline should no longer be used in the ambulatory management of this disease.OBJECTIVE
The author suggests an alternate approach to theophylline dosing as a means of resolving the current controversy.SUMMARY
Because of the log-linear relationship between bronchodilation and blood level, little bronchodilator efficacy is lost by using a target therapeutic theophylline blood level of 10 ± 2 μg/mL. This target provides a greater range between therapeutic and toxic blood levels than the 17 ± 2 μg/mL therapeutic target blood level that has also been recommended.CONCLUSIONS
Because theophylline has a different mode of action than the sympathomimetic or anticholinergic drugs, it continues to have a useful place in the ambulatory management of chronic obstructive pulmonary disease.